Duality Biotherapeutics Hits PFS Milestone with DB‑1303/BNT323 in HER2‑Positive Breast Cancer
China‑based Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Phase III study of the HER2‑targeting antibody‑drug...
Innovent Biologics Announces Strong Phase II Results for Tigulixostat in Chinese Gout Patients
China-based Innovent Biologics Inc. (HKG: 1801) revealed that its next‑generation xanthine oxidase inhibitor (XOI), tigulixostat...
XWPharma Secures $205 M Valiloxybate Deal with Avadel
China‑based XWPharma Ltd. announced today that it has entered into an exclusive licensing agreement with...
FDA Launches “Green List” to Shield U.S. Markets from Unsafe GLP‑1 APIs
The U.S. Food and Drug Administration (FDA) today announced a new “green list” import alert...
InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL
Shanghai‑based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September 8, 2025 that its Bruton’s tyrosine kinase...
Regenelead Secures NMPA Approval for RGL‑305 Cell Therapy in Advanced Malignant Tumors
On September 2, 2025, Shanghai‑based Regenelead announced that its internally developed cell‑therapy product RGL‑305 Injection received...
Takeda Secures FDA Approval for VONVENDI’s Expanded Use in Adult and Pediatric VWD
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) today confirmed that the U.S. Food and Drug...
QuantumPharm XtalPi Secures Phase I Approval for PEP08, a Next‑Generation PRMT5 Inhibitor
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) announced a pivotal clinical milestone for...
Escugen and Huahui Health Form Exclusive Partnership to Develop First‑in‑Class ADC for Solid Tumors
Shanghai‑based Escugen and Beijing‑headquartered Huahui Health have announced a global, exclusive cooperation agreement to develop...
NHSA Releases Draft Regulations to Tighten Medical Insurance Funds Oversight
On September 7, 2025, China’s National Healthcare Security Administration (NHSA) issued the Draft Implementation Rules for the...
Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies
US-based Gilead Sciences’ (NASDAQ: GILD) subsidiary Kite Pharma has officially ended its $2.3 billion collaboration with Shoreline...
Junshi Biosciences’ JS005 IL‑17A Antibody Shows Promise in Phase III Psoriasis Trial
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that its proprietary recombinant humanized...
Hengrui’s RSS0393 PDE4 Inhibitor Approved for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its proprietary topical RSS0393...
Hengrui’s HRS‑4729 GLP‑1 Triple Agonist Receives NMPA Approval for MASLD & MASH
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its investigational drug HRS‑4729...
Innovent’s Xinbimin IGF‑1R Antibody Approved in Macau
China-based Innovent Biologics Inc. (HKG: 1801) announced that the Macau Special Administrative Region drug authority...
TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced the first patient dose in an open‑label, multi‑center...
Simcere Launches Quviviq, New Insomnia Therapy in China
Jiangsu Simcere Pharmaceutical Co., Ltd. (HKG: 2096) announced the nationwide launch of its first prescription...
Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced an exclusive licensing arrangement with...
Dongcheng Pharma to Spin‑Off Lannacheng for HK Main Board Listing – Radiopharma Focus
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that it will spin off its...
Hengrui’s SHR‑A2009 ADC Gains NMPA Approval for HER3‑Targeted Tumor Therapy
China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the China National Medical...